Society for Immunotherapy of Cancer (SITC) 2022
Boston, MA
A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models.
SPEAKER : Ravikumar Muthuswamy
World Vaccine Congress Washington 2022
Washington | DC
Novel Vaccinia Enhanced Template (VET) Oncolytic Platform
SPEAKER : Steve Thorne
TGF β for Immuno-Oncology Drug Development
Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus
SPEAKER : Steve Thorne
13TH INTERNATIONAL ONCOLYTIC VIRUS CONFERENCEOncolytic Viruses Symposium
The VET Platform: Re-targeting Oncolytic Vaccinia Virus to Tumors through Expression of Chemokine Receptors
SPEAKER : Steve Thorne
Oncolytic Virotherapy Summit
Boston | MA
The Design of Oncolytic Viral Therapies for Intravenous Delivery
SPEAKER : Steve Thorne
Oncolytic Viruses Symposium
Oxford Global
A Dual Pipeline Strategy Bringing Potent Vaccinia-Based Oncolytic Immunotherapies to the Clinic
SPEAKER : Steve Thorne
